Moore Capital Management, LP Gilead Sciences, Inc. Transaction History

Moore Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $33.3 Million - $47.9 Million	-534,860 Reduced 89.16%	65,000 $5.58 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $23.8 Million - $27.1 Million	399,111 Added 198.81%	599,860 $37 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $3.31 Million - $3.73 Million	-57,359 Reduced 22.22%	200,749 $12.4 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $14.9 Million - $18.7 Million	258,108 New	258,108 $15.3 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $26.1 Million - $28.5 Million	-411,628 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $24.7 Million - $28.2 Million	411,628 New	411,628 $26.6 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $24.6 Million - $28.6 Million	-340,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $21.3 Million - $27.3 Million	340,000 New	340,000 $25.4 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.